SCHEMBL5200701

SCHEMBL5200701

O=C1c2ccccc2C(=O)N1c1ccc2cccnc2n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.54
ALDH1A1 P00352 4/20 0.54
GAA P10253 1/20 0.54
HTT P42858 4/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
LMNA P02545 4/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
HPGD P15428 2/20 0.41
POLB P06746 3/20 0.40
TP53 P04637 2/20 0.40
MMP2 P08253 2/20 0.40
PSMD14 O00487 1/20 0.40
HSD17B10 Q99714 2/20 0.40
TDP1 Q9NUW8 2/20 0.39
THRB P10828 1/20 0.39
BLM P54132 1/20 0.39
MAPT P10636 3/20 0.39
MITF O75030 1/20 0.39
CASP6 P55212 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11849277 0.82 ALDH1A1 (0.44) KDM4EALDH1A1GAAMEN1KMT2A
SCHEMBL5201507 0.77 ALDH1A1 (0.40) KDM4EALDH1A1GAAHTTMEN1
SCHEMBL11705831 0.77 ALDH1A1 (0.50) KDM4EALDH1A1GAAHTTMEN1
SCHEMBL7329332 0.77 MEN1 (0.42) KDM4EALDH1A1GAAHTTMEN1
SCHEMBL7329911 0.77 ALDH1A1 (0.40) KDM4EALDH1A1GAAHTTMEN1
SCHEMBL14336359 0.77 RECQL (0.42) KDM4EALDH1A1GAAMEN1KMT2A
SCHEMBL30046397 0.76 HTR1A (0.51) KDM4EALDH1A1GAAHTTMEN1
SCHEMBL11548784 0.76 HTR1A (0.51) KDM4EALDH1A1GAAHTTMEN1
SCHEMBL30817653 0.75 ALDH1A1 (0.73) KDM4EALDH1A1GAAHTTMEN1
SCHEMBL7479419 0.75 ALDH1A1 (0.73) KDM4EALDH1A1GAAHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7304158-B2 Method for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone) INDEVUS PHARMACEUTICALS, INC. (US) 2007-12-04 US claimed
US-20060194830-A1 Method for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone) INDEVUS PHARMACEUTICALS, INC. 2006-08-31 US claimed
US-7057047-B2 Methods for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2oxo-hexyl)-1-isoidolinone INDEVUS PHARMACEUTICALS, INC. (US) 2006-06-06 US claimed
EP-1490363-B1 METHODS OF PREPARATION OF THE 2-(7-CHLORO-1,8-NAPHTHYRIDINE-2-YL)-3-(5-METHYL-2-OXO-HEXYL)-1-ISOINDOLINONE INDEVUS PHARMACEUTICALS INC (US) 2006-01-25 EP claimed
US-20050288322-A1 Methods for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2oxo-hexyl)-1-isoidolinone INDEVUS PHARMACEUTICALS, INC. (US) 2005-12-29 US claimed
EP-1490363-A1 METHODS OF PREPARATION OF THE 2-(7-CHLORO-1,8-NAPHTHYRIDINE-2-YL)-3-(5-METHYL-2-OXO-HEXYL)-1-ISOINDOLINONE Warner-Lambert Company LLC (US) 2004-12-29 EP claimed
US-20030191315-A1 Methods for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone ENDO PHARMACEUTICALS INC. 2003-10-09 US claimed
WO-2003082870-A1 METHODS OF PREPARATION OF THE 2-(7-CHLORO-1,8-NAPHTHYRIDINE-2YL)-3-(5-METHYL-2-OXO-HEXYL)-1-ISOINDOLINONE WARNER-LAMBERT COMPANY LLC (US) 2003-10-09 WO claimed
US-7304158-B2 Method for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone) INDEVUS PHARMACEUTICALS, INC. (US) 2007-12-04 US disclosed
US-20060194830-A1 Method for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone) INDEVUS PHARMACEUTICALS, INC. 2006-08-31 US disclosed
US-7057047-B2 Methods for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2oxo-hexyl)-1-isoidolinone INDEVUS PHARMACEUTICALS, INC. (US) 2006-06-06 US disclosed
EP-1490363-B1 METHODS OF PREPARATION OF THE 2-(7-CHLORO-1,8-NAPHTHYRIDINE-2-YL)-3-(5-METHYL-2-OXO-HEXYL)-1-ISOINDOLINONE INDEVUS PHARMACEUTICALS INC (US) 2006-01-25 EP disclosed
US-20050288322-A1 Methods for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2oxo-hexyl)-1-isoidolinone INDEVUS PHARMACEUTICALS, INC. (US) 2005-12-29 US disclosed
US-6949653-B2 Methods for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone INDEVUS PHARMACEUTICALS, INC. (US) 2005-09-27 US disclosed
EP-1490363-A1 METHODS OF PREPARATION OF THE 2-(7-CHLORO-1,8-NAPHTHYRIDINE-2-YL)-3-(5-METHYL-2-OXO-HEXYL)-1-ISOINDOLINONE Warner-Lambert Company LLC (US) 2004-12-29 EP disclosed
US-20030191315-A1 Methods for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone ENDO PHARMACEUTICALS INC. 2003-10-09 US disclosed
WO-2003082870-A1 METHODS OF PREPARATION OF THE 2-(7-CHLORO-1,8-NAPHTHYRIDINE-2YL)-3-(5-METHYL-2-OXO-HEXYL)-1-ISOINDOLINONE WARNER-LAMBERT COMPANY LLC (US) 2003-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288322-A1 Methods for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2oxo-hexyl)-1-isoidolinone NT5C3B, NT5C, CYP2J2 KDM4E 3157/4885ALDH1A1 135/4885GAA 3316/4885
US-20030191315-A1 Methods for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone NT5C, NT5C3B, UGT8 KDM4E 3343/4885ALDH1A1 238/4885GAA 3060/4885
US-20060194830-A1 Method for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone) NT5C, NT5C3B, UGT8 KDM4E 3333/4885ALDH1A1 272/4885GAA 3354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.